Abstract

New challenges and the state of development of COVID-19 in connection with the spread of new strains of SARS-CoV-2 have been analyzed. Experience and knowledge in working with new means of protection of different types of vaccines are studied: both classic, based on inactivated virus or its fragment, and the new generation – with vector and genetic mRNA vaccines, as well as effective antiviral drugs. Biorisks and compliance with biosafety principles have been studied. The replenishment of the base of competencies for biotechnologists and pharmacists in the context of distance learning and response to the pandemic is considered. The new data were used to introduce and deepen knowledge about the new generation of vaccines and the dangers of dual use of experimental data in the development of new components of educational programs in "Biotechnology and Bioengineering" and “Pharmacy, Industrial Pharmacy”.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.